FlyteHealth Selected by CMS for Medicare ACCESS Model in Cardio-Kidney-Metabolic Care
FlyteHealth, a company specializing in precision cardio-kidney-metabolic care, has been recognized by CMS for its management of eCKM (enhanced Chronic Kidney Disease Management) as part of preparations for the ACCESS Model, a 10-year Medicare payment demonstration starting July 1, 2026. The ACCESS Model aims to enhance care delivery for chronic conditions related to hypertension, dyslipidemia, obesity, central adiposity, and prediabetes, which are key factors driving cardiovascular and kidney-related diseases. FlyteHealth's integrated virtual care model addresses these areas and has demonstrated significant clinical and economic outcomes. The company's approach to cardio-kidney-metabolic disease management is built around a dual-engine model supported by a multidisciplinary team, including community health workers, medical doctors, nurse practitioners, registered nurses, registered dietitians, and health coaches. This team delivers measurable improvements across cardio-kidney-metabolic risk factors, leveraging both clinical medication interventions and intensive behavioral interventions. FlyteHealth's model is designed specifically for Medicare-age adults and operates almost entirely virtually, facilitating scalable care delivery. FlyteHealth's real-world effectiveness is supported by robust data and a multi-year track record of serving the 65-plus Medicare population. Its virtual clinical medication and behavioral intervention framework is well-suited to meet the goals of the CMS ACCESS program, which seeks innovative and scalable solutions to improve management of chronic cardiometabolic diseases. FlyteHealth has expressed commitment to working with CMS and other partners to deploy its clinical expertise and technology infrastructure to millions of patients nationwide. The company employs advanced data analytics and artificial intelligence to provide cost-effective and sustainable care solutions for patients with prediabetes, diabetes, hypertension, hyperlipidemia, and obesity alongside related comorbidities. FlyteHealth integrates AI-driven clinical intelligence with digital tools and decision-support systems to translate complex medical evidence into practical, real-world care delivery. This approach supports improved metabolic health outcomes, optimized medication use, and reduced total cost of care within the Medicare population. FlyteHealth's inclusion in the upcoming ACCESS Model highlights the growing role of technology-enabled chronic disease management programs in Medicare. By focusing on upstream cardiometabolic drivers, the program seeks to reduce the incidence and progression of major chronic illnesses, thus impacting Medicare spending and patient quality of life. The collaboration with CMS reflects an industry trend toward value-based care models emphasizing preventive and integrated interventions for complex chronic diseases.